Management discusses results from the donanemab TRAILBLAZER-ALZ 2 clinical trial, as well as the broader landscape in Alzheimer’s disease, on a conference call to be held on July 17 at 1:30 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly’s (NYSE:LLY) Alzheimer’s Drug Inches Closer to FDA Approval
- Eli Lilly presents full results from Phase 3 TRAILBLAZER-ALZ 2 study
- Sangamo enters research evaluation, option agreement with Prevail
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Microsoft upgraded, AT&T downgraded: Wall Street’s top analyst calls